［1］ 邹仲之，李继承.组织学与胚胎学［M］.7版.北京：人民卫生出版社，2011，34-35.
［2］ Begley C G, Basser R L.Biologic and structural difference of thrombopoietic growth factors［J］.Semin Hematol,2000,37:19-27.
［3］ 白春梅，徐光勋，赵永强，等.重组人血小板生成素治疗实体肿瘤患者化疗后血小板减少的多中心临床试验［J］.中国医学科学院学报，2004,26:437-441.
［4］ Vadhan-Raj S,Verschrasegen C F,Bueso-Ramos C,et al.Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer［J］.Ann Intern Med,2000,132:364-368
［5］ Elting L S,Rubenstein E B,Martin C G, et al.Incidence,cost,and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia［J］.J Clin Oncol,2001,19:1137-1146.
［6］ Kaushansky K.Thrombopoietin［J］.N Engl J Med,1998,339:746-754.
［7］ Murryay L J,Luens K M,Estrada M F, et al.Thrombopoietin mobilizes CD34+cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis［J］.Exp Hematol,1998,26:207-216.[ZK)]
(2012-05-23